ErbB3 mRNA Expression Correlated with Specific Clinicopathologic Features of Japanese Lung Cancers

Journal of Surgical Research

Volumn 146, Issue 1, 2008, Pages 43-48

  Kawano, Osamu ^a   Sasaki, Hidefumi ^a   Endo, Katsuhiko ^a   Suzuki, Eriko ^a   Haneda, Hiroshi ^a   Yukiue, Haruhiro ^a   Kobayashi, Yoshihiro ^a   Yano, Motoki ^a   Fujii, Yoshitaka ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

adenocarcinoma; EGFR; ErbB3; lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 3; MESSENGER RNA;

ADULT; ARTICLE; CIGARETTE SMOKING; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; JAPANESE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SEX DIFFERENCE; UNIVERSITY HOSPITAL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; HUMANS; JAPAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-3; RNA, MESSENGER; SEX CHARACTERISTICS;

EID: 41149116835     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2007.05.030     Document Type: Article

References (26)

1. Prenzel N., Fischer O.M., Streit S., et al. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endcr Relat Cancer 8 (2001) 11
2. erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci USA 91 (1994) 8132
3. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2 (2001) 127
4. Chan D.C., Soriano A., Kane M.A., et al. Biology of lung cancer. In: Hansen H.H. (Ed). Textbook of lung cancer (2000), Martin Dunitz, London 53-54
5. D'Amico T.A., Massey M., Herndon J.E., et al. A biologic risk model for stage I lung cancer: Immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg 117 (1999) 736
6. Yi E.S., Harclerode D., Gondo M., et al. High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas. Mod Pathol 10 (1997) 142
7. Lai W.W., Chen F.F., Wu M.H., et al. Immunohistochemical analysis of epidermal growth factor receptor family members in stage I non-small cell lung cancer. Ann Thorac Surg 72 (2001) 1868
8. Amann J., Kalyankrishna S., Massion P.P., et al. Aberrant epidermal growth factor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 65 (2005) 226
9. Engleman J.A., Janne P.A., Mermel C., et al. ErbB3 mediates phosphoinositide 3-kinase activity in gefitinib sensitive non-small cell lung cell cancer cell lines. Proc Natl Acad Sci USA 102 (2005) 3788
10. Fujimoto N., Wislez M., Zhang J., et al. High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. Cancer Res 65 (2005) 11478
11. th ed. 5 (1999), The Japan Lung Cancer Society, Tokyo 1-177
12. Endo K., Konishi A., Sasaki H., et al. Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. Lung Cancer 50 (2006) 375
13. Riese II D.J., and Stern D.F. Specificity within the EGF family/ErbB receptor family signaling network. BioEssays 20 (1998) 41
14. Olayioye M.A., Neve R.M., Lane H.A., et al. The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J 19 (2000) 3159
15. Sithanandam G., Fornwald L.W., Fields J., et al. Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549. Oncogene 24 (2005) 1847
16. Poller D.N., Spendlove I., Baker C., et al. Production and characterization of a polyclonal antibody to the c-erbB3 protein: Examination of c-erbB3 protein expression in adenocarcinoma. J Pathol 168 (1992) 275
17. Cappuzzo F., Toschi L., Domenichini I., et al. HER3 genomic gain and sensitivity to gefitinib in advanced non small-cell lung cancer patients. Br J Cancer 93 (2005) 1334
18. Ono M., Hirata A., Kometani T., et al. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for prolification. Mol Cancer Ther 3 (2004) 465
19. Engelman J.A., and Cantley L.C. The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 12 (2006) 4372s
20. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497
21. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129
22. Pao W., Miller V., Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101 (2004) 13306
23. Sasaki H., Shimizu S., Endo K., et al. EGFR and erbB2 mutation status in Japanese lung cancer patients. Int J Cancer 118 (2006) 180
24. Sasaki H., Endo K., Mizuno K., et al. EGFR mutation status and prognosis for gefitinib treatment in Japanese lung cancer. Lung Cancer 51 (2006) 135
25. Hua K.T., Way T.D., and Lin J.K. Pentagalloyglucose inhibits estrogen receptor alpha by lysosome-dependent depletion and modulates EebB/PI3K/Akt pathway in human breast cancer MCF-7 cells. Mol Carcinog 45 (2006) 551
26. St-Laurent V., Sanchez M., Charbonneau C., et al. Selective hormone-dependent repression of estrogen receptor beta by a p38-activated ErbB2/ErbB3 pathway. J Steroid Biochem Mol Biol 94 (2005) 23